inclusion criteria: * male or female participants ≥65 years of age at the time of consent * participating or participated in study c4591001, received 2 doses of 30 µg bnt162b2 with the second dose given ≥6 months prior to the first vaccination in this study, and have not received a third dose of bnt162b2 * adults determined by clinical assessment, including medical history and clinical judgement, to be eligible for the study, including adults with preexisting stable disease * adults who have no history of ever receiving a pneumococcal vaccine, or received a licensed pneumococcal vaccination ≥12 months prior to the first vaccination in this study

inclusion criteria: * male or female participants ≥65 years of age at the time of consent * participating or participated in study c4591001, received 2 doses of 30 µg bnt162b2 with the second dose given ≥6 months prior to the first vaccination in this study, and have not received a third dose of bnt162b2 * adults determined by clinical assessment, including medical history and clinical judgement, to be eligible for the study, including adults with preexisting stable disease * adults who have no history of ever receiving a pneumococcal vaccine, or received a licensed pneumococcal vaccination ≥12 months prior to the first vaccination in this study

inclusion criteria: - male or female participants ≥65 years of age at the time of consent - participating or participated in study c4591001, received 2 doses of 30 µg bnt162b2 with the second dose given ≥6 months prior to the first vaccination in this study, and have not received a third dose of bnt162b2 - adults determined by clinical assessment, including medical history and clinical judgement, to be eligible for the study, including adults with preexisting stable disease - adults who have no history of ever receiving a pneumococcal vaccine, or received a licensed pneumococcal vaccination ≥12 months prior to the first vaccination in this study

inclusion criteria: - male or female participants ≥65 years of age at the time of consent - participating or participated in study c4591001, received 2 doses of 30 µg bnt162b2 with the second dose given ≥6 months prior to the first vaccination in this study, and have not received a third dose of bnt162b2 - adults determined by clinical assessment, including medical history and clinical judgement, to be eligible for the study, including adults with preexisting stable disease - adults who have no history of ever receiving a pneumococcal vaccine, or received a licensed pneumococcal vaccination ≥12 months prior to the first vaccination in this study